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FTY720-induced lymphocyte homing modulates post-
transplant preservation/reperfusion injury.
Background. A novel immunomodulator, FTY720, modu-
lates lymphocyte migration to injured tissues via enhanced
lymphocyte sequestration to secondary lymphoid organs. We
tested whether or not single-dose FTY720 (0.5 mg/kg) pre-
treatment rescues renal grafts from post-transplant preserva-
tion/reperfusion injury.
Methods. Rat renal grafts were cold-preserved in Univer-
sity of Wisconsin (UW) solution for 4 hours and then trans-
planted into syngeneic or allogeneic recipients that received a
single dose of FTY720 24 hours before transplantation. Flow
cytometry analysis of peripheral blood and lymph nodes was
performed to confirm the biologic effect of FTY720. Grafts
were harvested after 24 hours. Renal sections were examined
histologically and stained for intracellular adhesion molecule-1
(ICAM-1), vascular cellular adhesion molecule-1 (VCAM-1),
platelet endothelial cellular adhesion molecule-1 (PECAM-1),
major histocompatibility complex (MHC) class II, and inflam-
matory cells. Interleukin-1 (IL-1) production was determined
in renal protein extracts.
Results. FTY720 pretreatment significantly increased CD3+
T-cell sequestration to lymph nodes in the face of peripheral
lymphopenia. Isografts and allografts from the FTY720-treated
groups did not develop increased creatinine (0.55 ± 0.12 in iso-
grafts and 0.62 ± 0.08 mg/dL in allografts), compared with ve-
hicle controls (2.28 ± 0.20 in isografts and 2.24 ± 0.18 mg/dL in
allografts). Kidneys from FTY720-treated groups also showed
lower acute tubular damage scores. Furthermore, FTY720
decreased neutrophil influx, although circulating neutrophils
were unchanged. FTY720 also prevented postischemic IL-1
intragraft production not affecting infiltration with recipient
ED-1+macrophages and MHC class II–positive cells. Expres-
sion of ICAM-1, VCAM-1, and PECAM did not differ among
groups.
Conclusion. FTY720 ameliorated morphologic and func-
tional consequences of post-transplant reperfusion injury. Thus,
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FTY720-induced peripheral T-cell absence may influence in-
tragraft IL-1 production and neutrophil infiltration, despite
proadhesive endothelial properties. FTY720 may broaden the
utility in renal transplantation as a pretreatment strategy against
preservation/reperfusion injury.
Delayed graft function caused by ischemia/reperfusion
injury (I/RI) is the major complication in the immediate
post-transplant period. Grafts that fail to function imme-
diately are more susceptible to acute rejection and ear-
lier onset of chronic allograft nephropathy [1]. Although
currently used immunosuppressive agents safely reduce
the incidence of acute rejection episodes, there is no
protocol currently available to ameliorate early and late
consequences of I/RI [2]. FTY720 is a new immunomod-
ulator that initiates sequestration of lymphocytes to sec-
ondary lymphoid organs and reduces the number of circu-
latory lymphocytes [3]. FTY720 promises to be a nontoxic
new drug for treatment of rejection and autoimmune dis-
eases [4]. Recent studies implicate T cells as an important
leukocyte subset in the induction of postischemic injury in
liver [5] and kidney [6]. However, these studies were per-
formed in non-transplant models. In transplant kidneys,
the detrimental cascade of chronic allograft nephropa-
thy may be influenced by early changes that result from
I/RI. Efficacy in preventing I/RI, rejection, and chronic
functional deterioration would be of great clinical utility.
We hypothesized that FTY720 mediated T-cell migration
to secondary lymphoid tissue may interefere with postis-
chemic inflammatory responses in the renal graft and
confer protection from post-transplant I/RI. We inves-
tigated the effect of a single FTY720 pretreatment dose
on postischemic acute intragraft inflammatory response,
lymphocyte homing, and functional and morphologic fea-
tures of post-tranplant reperfusion injury in isogeneic
and low-responder allogeneic rat renal transplantation
models. Renal grafts were exposed to 4 hours of cold
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preservation that reproducibly induced delayed graft
function [7].
METHODS
Animals and transplantation surgery
Inbred male Fischer (F344) and Lewis (Lew, RT1)
rats weighing 150 to 200 g were purchased from Harlan-
Winkelman (Sulzbach, West Germany). The animals had
free access to tap water and a standard rat diet (No.
C-1000, Altromin; Lage, West Germany). They were kept
under regular lighting conditions (lights on at 6:00 and off
at 18:00) at a constant temperature of 24◦C. All surgical
procedures were approved by local authorities according
to guidelines corresponding to the American Physiologi-
cal Society. Twenty-four hours before transplantation the
recipient rats received per gavage a single dose of FTY720
dissolved in water (0.5 mg/kg) or vehicle and were fasted
overnight before surgery. In the allogeneic model, F344
rat kidneys were transplanted into Lewis recipients, and
in the isogeneic model, Lewis rats were both donors and
recipients.
Donor animals were prepared as previously described
[8]. Perfusion (ex vivo) with 10 mL cold University of
Wisconsin (UW) solution followed. Finally, the kidney
was placed in cold UW solution (0–4◦C) for 4 hours. Re-
cipient Lewis rats were anesthetized with ketamine and
the left native kidney was removed. Anastomoses of the
vessels and the ureter were performed end-to-end using
10–0 prolene. The anastomosis time averaged 30 min-
utes. Upon the completion of anastomoses, the right na-
tive kidney was removed as well. Both native kidneys
were preserved for later use as controls. Five animals per
treatment were killed 24 hours after transplantation (N =
20 transplants). Apart from pretreatment with FTY720,
animals did not receive any other immunosuppression or
medication during the study. Venous blood was obtained
from the retrorobital plexus for serum creatinine concen-
tration determined with automated methods.
Cell preparation and flow cytometry
Peripheral blood was collected from the aortic blood
of recipient Lew rats. Peripheral lymph nodes were
harvested 24 hours after treatment with FTY720 or
vehicle, and 24 hours after transplantation (48 hours
after FTY720 administration), respectively. Rat periph-
eral blood mononuclear cells (PBMCs) were prepared
after removal of erythrocytes using BD-lysing solution
(Becton-Dickinson, Heidelberg, West Germany). Lymph
nodes were separately minced with a razor blade. Filter-
ing the cell suspension with phosphate-buffered saline
solution (PBS) through a syringe filled with gauze elim-
inated tissue debris. Finally, cells of all samples were re-
suspended in aliquots [200 lL fluorescence-activated cell
sorter (FACS) flow] and stained with the correspond-
ing monoclonal antibodies (5 lL) at 4◦C in the dark for
30 minutes. After staining, 3 to 5 mL PBS were added
to each sample and centrifuged (350g, 5 minutes) in or-
der to wash the cells. Cells were washed twice and then
fixed with BD-fixation buffer (1×; Becton-Dickinson).
Flow cytometry analysis was performed with FACS Cal-
ibur (Becton Dickinson). Statistical analysis of the FACS
data was performed with CellQuest (Becton-Dickinson).
Antibodies
Antibodies used for FACS were CD3-FITC (clone
G41.8, isotype IgG3k), CD4-PE (clone OX-35, iso-
type IgG2k), CD8-PE (clone OX-8, isotype IgG1k),
B-cells-CD45RA-FITC (clone OX-33, isotype IgG1k),
neutrophils (clone His 48, isotype IgMk), CD45-FITC
(clone OX-1, isotype IgG1k), and isotype controls IgG1k-
FITC and IgG1k-PE (both clone A112-2), IgG2k-PE
(clone G155-178), IgG3k-FITC (clone J606), and IgMk
(clone G155-228), all from Becton- Dickinson. Abs used
for immunohistochemical staining included: monoclon-
als for PECAM-1 (CD31, clone TLD-4E8), neutrophils
(His 48), monocytes-macrophages (ED-1), MHC class
II (clone OX-18), CD8 lymphocytes (clone OX-8), all
obtained from Serotec (Oxford, UK); ICAM-1 VCAM-
1 (CD106, clone 51–1069) from Becton-Dickinson (San
Diego, CA, USA).
ELISA
Renal IL-1 expression was quantified by enzyme-
linked immunosorbent assay (ELISA) kit (R&D Sys-
tems, Minneapolis, MN, USA). Briefly, frozen kidneys
were thawed and minced. The whole kidney homogenates
were then centrifuged (350g, 5 minutes) and four aliquots
(100 lL) of the supernatant of each sample were incu-
bated with the capture anti-IL-1 mAb coated wells for
two hours. After repeated washing steps and incubation
with an avidin-coupled detection mAb (anti-IL-1) and
streptavidin-horseradish peroxidase, the peroxidase sub-
strate (TMB) was added. The color reaction was termi-
nated with H2SO4 and extintion measured at 450 nm
with an ELISA reader (Dynatech). IL-1 concentration
was calculated with an IL-1 standard row (Dynatech,
Chantilly, VA, USA).
Immunohistochemistry
Immunohistochemistry was carried out as we previ-
ously described [8]. The immunoreactivity was visualized
with an alkaline phosphatase antialkaline phosphatase
(APAAP) complex (Dako, Carpinteria, CA, USA). For
detection and development, we used the neufuchsin-
naphtol-As-Bi-phosphate substrate (Merck, Darmstadt,
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Fig. 1. FTY720, but not vehicle, induces lym-
phocytopenia and increases homing of lym-
phocytes to lymph nodes 24 hours after a
single-dose administration. The percentage of
peripheral leukocyte subsets is shown accord-
ing to granularity in vehicle (A) and FTY720
pretreated animals (B). Increased density of
lymphocytes in peripheral lymph nodes after
FTY720 (D) is shown, compared with vehicle
treatment (C).
West Germany) as described. Negative control stainings
were performed by incubation with corresponding iso-
type controls instead of primary Ab.
Semiquantitative data on the infiltration of His48+
neutrophils, ED-1+ monocytes/macrophages, and MHC
class II–positive cells was determined using KS 300 3.0
imaging system and Axioplan 2 microscope (Zeiss, Jena,
West Germany). Positively labeled cells in the each sec-
tion were counted in 15 randomly chosen fields corre-
sponding to an area of 63.525 lm2. The means for five
rats at any one time point were then grouped together
to obtain a final mean and SEM. Tissue specimens were
scored in a blinded manner.
Renal transplant histology
The kidneys fixed in 10% buffered formalin were de-
hydrated and then embedded in paraffin. Sections (3 lm)
were stained with hematoxylin and eosin using standard
procedures. Examination and scoring of the sections of
each renal graft for hallmarks of acute tubular necrosis
(ATN) was conducted on a blinded basis as previously
described. The degree of renal damage was semiquanti-
tatively evaluated using tubular necrosis score based on a
scale in which 0 represented no abnormalities, 1 stood for
slight (up to 20%), 2 for moderate (20% to 40%), 3 for
severe (40% to 60%), and 4 for total necrosis affecting
more than 80% of renal parenchyma, respectively.
Statistical analysis
Statistical analysis was carried out on a G4 Macintosh
computer (Apple, Inc., Cupertino, CA, USA) with a com-
mercially available program (Statview, Cricket Software,
Inc., Philadelphia, PA, USA). All values are reported as
mean ± SEM. The results between groups were com-
pared using nonparametric Kruskal-Wallis and Mann-
Whitney U test. A P value < 0.05 was considered as
significant.
RESULTS
We first compared effects of FTY720 to vehicle on
leukocyte subsets in the peripheral blood and secondary
lymphoid tissue in recipient strain animals after 24 hours.
Figure 1A shows normal leukocyte subset content of pe-
ripheral blood according to granularity in CD45-positive
cells expressed as percentage of different cell popula-
tions. As shown in Fig. 1B, the number of lympho-
cytes was significantly decreased in peripheral blood
24 hours after single FTY720 administration (from 20.5%
to 2.2%). There was also a significant decrease in mono-
cytes (from 12.6% to 5.5%), although to a lesser extent
compared with lymphocytes. Other nonlymphoid cells
such as eosinophils and neutrophils were not significantly
influenced. Compared with lymphocyte content in vehi-
cle (Fig. 1C), FTY720 increased homing of lymphocytes
into peripheral lymph nodes (Fig. 1D).
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Fig. 2. FTY720-treated animals are functionally protected from post-
transplant ischemia/reperfusion injury (I/RI). FTY720-treated syn-
geneic (iso) and allogeneic (allo) recipients show significant reduction
in serum creatinine concentration 24 hours after transplantation com-
pared with vehicle- (v) treated transplanted animals. ∗P ≤ 0.05 vs. ve-
hicle treatment.
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Fig. 3. Acute tubular necrosis score in renal isografts and allografts
pretreated with FTY720 or vehicle 24 hours after transplantation. ∗P ≤
0.05 vs. vehicle treatment.
Renal function parameters in rats treated with FTY720
or vehicle are shown in Figure 2. Creatinine concen-
trations in serum were increased 24 hours after trans-
plantation 2.28 ± 0.20 (isografts) and 2.24 ± 0.18 mg/dL
(allografts) in animals that received vehicle treatment. In
contrast, animals that were administered FTY720 showed
significantly lower serum creatinine values 0.55 ± 0.12
(isografts) versus 0.62 ± 0.08 mg/dL (allografts).
A semiquantitative grading scale for ATN (comparing
4 kidneys from each group) 24 hours after transplantation
is shown in Figure 3. Morphologic changes were compara-
0
10
20
30
H
is
48
+ 
ce
lls
/F
V
Iso
 + 
v
All
o +
 
v
All
o +
 
FT
Y
Iso
 + 
FT
Y
A
0
200
400
600
800
IL
-1
,
pg
/m
L
Iso
 + 
v
All
o +
 
v
All
o +
 
FT
Y
Iso
 + 
FT
Y
B
Fig. 4. FTY720 treatment reduces (A) intragraft neutrophil infiltration
and (B) interleukin-1 (IL-1) production. ∗P ≤ 0.05 vs. vehicle treatment.
Fig. 5. Effect of FTY720 on the percentage of His48-positive neu-
trophils in peripheral blood in recipient animals 24 hours before and 24
hours after transplantation.
ble to the functional parameters in experimental groups.
Both isografts and allografts treated with FTY720 devel-
oped only mild changes (range 1), while vehicle treated
animals developed more severe changes (range 2 to 3).
Neutrophils are major effector cells responsible for
functional deterioration due to the reperfusion injury. To
investigate how FTY720 treatment may influence inflam-
matory responses during reperfusion injury, we quanti-
fied the His 48-positive cells in the experimental groups.
As depicted in Figure 4A, FTY720 treatment significantly
decreased neutrophil infiltration compared with vehicle-
treated isogeneic and allogeneic transplants. Neutrophils
were mainly found within the glomeruli and in perivascu-
lar and interstitial spaces (not shown), in accordance with
our previous results [8]. Besides tumor necrosis factor-a
(TNF-a), IL-1 is a most potent attractant for neutrophils.
We obtained a significantly reduced production of IL-1
(pg/mL) in FTY720-treated isografts and allografts com-
pared with vehicle isografts and allografts (Fig. 4B).
To examine whether or not FTY720 treatment may
systemically influence neutrophil content, we compared
the percentage of His 48-positive cells in the periph-
eral blood from vehicle versus FTY720-treated animals
24 hours after transplantation. As shown in Figure 5,
there was no significant difference in the peripheral blood
neutrophil count between vehicle (18.7%; Fig. 5A) and
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Fig. 6. Flow cytometry for the percentage of CD4+ lymphocytes
24 hours after transplantation. Compared with vehicle (A) and (C),
FTY720 depletes CD4+ lymphocytes from peripheral blood (B) and
increases homing to peripheral lymph nodes (D).
FTY720-treated animals (15.1%; Fig. 5B). Thus, FTY720-
mediated reduction in intragraft neutrophil infiltration is
not a result of peripheral depletion.
To analyze effect of FTY720 on T lymphocyte subsets,
we studied CD4 and CD8 lymphocytes by flow cytom-
etry (FACS) in FTY720-treated and vehicle-treated an-
imals 24 hours after transplantation. We observed that
compared with vehicle (Fig. 6A), treatment with FTY720
resulted in a nearly complete disappearance of CD4+
T cells from the peripheral blood (2.5%; Fig. 6B) and
increased homing of CD4+ T cells to lymph nodes (60%;
Fig. 6D). FTY720 also increased homing of CD8+ T-cells
from peripheral blood (2.7%) to lymph nodes (21.5%)
(Fig. 7). We further studied whether or not FTY720 treat-
ment modulates intragraft response to injury mediated by
endothelial (ED)-1 monocytes or MHC class II–positive
cells. Contrary to our expectations, there was no differ-
ence in ED-1–positive (Fig. 8A) or MHC class II cell in-
filtration (Fig. 8B) between the isografts and allografts
treated with FTY720 or vehicle. Thus, increased homing
of lymphocytes to secondary lymphocyte tissue has no
effect on ED-1– and MHC class II–positive cells.
Enhanced inflammatory cell infiltration during post-
transplant reperfusion injury relates to increased en-
dothelial expression of adhesion molecules like ICAM-1,
PECAM-1, or VCAM-1, as we had shown earlier [8]. We
observed intensive staining of ICAM-1 in tubular, inter-
stitial cells, and on the endothelium of capillaries and
arterioles 24 hours’ post-transplant to the similar extent
in all transplants, independent of the treatement (Fig. 9
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Fig. 7. Flow cytometry for the percentage of CD8+ lymphocytes 24
hours after transplantation. Shown are CD8+ content in peripheral
blood (A) and in lymph nodes (C) in vehicle. FTY720 depletes CD4+
lymphocytes from peripheral blood (B) and increases homing to pe-
ripheral lymph nodes (D).
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Fig. 8. Number of intragraft infiltrating endothelial-1 (ED-1)+ mono-
cytes/macrophages (A) and major histocompatibility complex (MHC)
class II–positive cells (B) in FTY720 versus vehicle- (v) pretreated iso-
grafts (iso) and allografts (allo).
A and B). There was also no difference in microvascu-
lar PECAM-1 expression among groups (Fig. 9C and D).
Finally, endothelium and smooth muscle cells of arteri-
oles in all groups stained positive for VCAM-1 24 hours‘
post-transplant (Fig. 9 E and F).
DISCUSSION
Our study was intended to examine a possible pro-
tective role of FTY720-mediated T-cell sequestration to
secondary lymphoid tissue in post-transplant reperfusion
injury induced by prolonged cold ischemia. A single-dose
FTY720 pretreatment induced peripheral lymphocytope-
nia and ameliorated structural and functional injury in an
Dragun et al: FTY720 and post-transplant reperfusion injury 1081
Fig. 9. Expression of endothelial adhesion molecules 24 hours after transplantation. Intracellular adhesion molecule-1 (ICAM-1) immunostaining
in renal allograft treated with vehicle (A) or FTY720 (B). Platelet endothelial cell adhesion molecule-1 (PECAM-1) expression in renal allograft
treated with vehicle (C) or FTY720 (D) is shown. Vascular cellular adhesion molecule-1 (VCAM-1) in renal allograft treated with vehicle (E) or
FTY720 (F).
experimental rat model of renal transplantation. FTY720
treatment clearly reduced intragraft neutrophil infiltra-
tion and IL-1 production, despite lack of effect on the
up-regulation of ICAM-1 and VCAM-1 expression or dis-
tribution of PECAM-1. Intragraft monocyte and MHC
class II cell infiltration was not influenced. There was no
difference in the extent and nature of FTY720-mediated
protection between isografts and allografts. This finding is
in accord with the data from our earlier study in which we
reported no difference in the early inflammatory mech-
anisms between the syngeneic and low responder allo-
geneic strain combinations [8].
Current evidence indicates a role for T-cells as modula-
tors of I/RI in native kidneys [9]. T-cell–deficient (nu/nu
mice) were protected from functional and structural con-
sequences of I/RI induced by cross-clamping of renal
pedicles [6]. The protective effect was abolished through
the adoptive transfer of T-cells from wild-type animals [6].
In this study CD4, but not CD8, T-cell deficiency provided
protection from postischemic dysfunction, although CD4
deficiency had no effect on postischemic neutrophil and
monocyte infiltration [6]. In our study both CD4 and CD8
subsets were affected by FTY720 treatment to a simi-
lar extent. Therapeutic effect of FTY720 in experimental
models of rejection and autoimmune disease is attributed
to a decrease in peripheral lymphocyte counts [3] that
we also have shown in our model. We also recently ob-
served similar effects in stable renal allografts during the
phase I clinical study [10]. Thus, the functional and struc-
tural protection achieved by FTY720 treatment in our
experimental setting was due to enhanced sequestration
of T lymphocytes into secondary lymphoid tissue. The
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pathogenesis of post-transplant reperfusion injury in-
volves a complex interplay of endothelial and epithelial
factors, with the interstitium comprising an acute inflam-
matory response due to proadhesive activated endothe-
lium and subsequent tissue infiltration with leukocytes
[11].
The reduction in intragraft neutrophil infiltration and
secretion of IL-1 were associated with the protection from
the tubular necrosis and the transplant dysfunction in
FTY720 treatment group. Because FTY720 had no effect
on the number of neutrophils in peripheral blood before
and after transplant, it is likely that the absence of lym-
phocytes in peripheral blood was decisive for neutrophil
infiltration. Similar results were obtained in a mouse
model of liver lobar I/RI, where protection from injury
in CD4 T-cell–deficient mice was attributed to 10-fold
reduced neutrophil infiltration [5]. In experimental stud-
ies employing native kidneys, neutrophil infiltration has
been questioned because of the cross-reactivity of His-48
antibody with monocytes [12]. However, neutrophils are
a consistent finding in the biopsies of transplanted human
kidneys in majority of studies [11, 13–15]. To exclude pos-
sible cross-reactivity, we examined neutrophil and mono-
cyte cell infiltration in serial sections. The few cells that
were His 48 positive colocalized with ED-1–positive cells.
Interestingly, we were able to find only occasional CD4+
and CD8+ positive cell infiltrates per section in vehicle-
treated animals (not shown). We suggest that CD4+ lym-
phocytes do not infiltrate the kidney but only adhere to
the endothelium of vasa recta. They provide a transactiva-
tion signal for other inflammatory cells as early as 2 hours
after reperfusion of the transplant, as demonstrrated in
studies of T-cell kinetics in ischemia-reflow of the native
kidney [16]. Thus, FTY720-induced lymphocyte seques-
tration might have precluded this early transactivation
effect [16].
We also demonstrated that the neutrophil-mediated
acute inflammatory response was attenuated despite ab-
sence of change in expression and distribution of en-
dothelial adhesion molecules ICAM-1, VCAM-1, and
PECAM-1. Similar findings were obtained in a recent
study of ischemia-reflow in native kidneys. The inves-
tigators employed IL-1 receptor and TNF-receptor 1–
deficient mice. They implicated a potential involvement
of other cytokine pathways in the regulation of adhesion
molecule expression after ischemia [17]. Even though
we cannot offer definite functional explanation for this
finding, it is likely that the repertoire of endothelial cell
gene expression that occurs as a response to inury [18]
after reperfusion cannot be influenced by FTY720. We
speculate that FTY720 may rather interfere with pro-
cesses involved in the stabilization of endothelial bar-
rier. Recently, it has been reported that phosphorylated
form of FTY720 acts as an agonist for sphingosine
1-phosphate receptors [19]. Sphingosine 1-phosphate is
essential for the formation of vascular junctions and
maintenance of endothelial layer [20]. Another expla-
nation may be that FTY720 alters sensitivity to inflam-
matory chemokines through sphingosine 1-phosphate
receptors. Thus, neutrophil infiltration may be inhibited
upstream from endothelial adhesion molecules. Our fur-
ther finding was that peripheral monocyte counts were
reduced by FTY720 treatment, although the dense mono-
cytic infiltrates adjacent to the vessels expressing VCAM-
1 were not affected. MHC class II–positive infiltrates
and MHC class II expression in tubular epithelia were
also not influenced. The systemic reduction in monocyte
counts may have had no functional relevance in our study,
as the regulation of monocyte/macrophage response is
highly dependent on the local tissue microenviroment
[21]. In the human phase I trial, the number of peripheral
monocytes was not influenced by single FTY720 doses
[22]. A precise dissection of T-cell–dependent monocyte
responses is beyond the scope of our study. Clearly, mech-
anisms through which FTY720 modulates I/RI after re-
nal transplantation are more complex than we initially
anticipated. However, we believe our observations may
have clinical relevance for future therapy of transplant
patients.
Despite a wide spectrum of T-cell therapeutic agents
there are presently no effective modes to decrease the
incidence of delayed graft function, or to influence the
later detrimental consequences. Calcineurin inhibitors
used for basis immunosuppression promote endothelial
injury and renal vasoconstriction, thereby worsening de-
layed graft function [23]. The antiproliferative agent my-
cophenolate mofetil (MMF) acts protective in I/RI of
heart transplants [24]. While one study in I/RI caused
by bilateral artery occlusion in native rat kidneys reports
beneficial effect of MMF through decreased ICAM-1 ex-
pression and less monocytic and lymphocytic infiltrates
[25], in the other study MMF interfered negatively with
regeneration processes by reduced interstitial cellular re-
sponse in model of toxic acute renal failure [26]. Ag-
gressive T-cell depletion from spleen and lymph nodes
using triple antibody combinations acted protective in
murine native kidney I/RI model [27]. OKT3 prophy-
laxis in patients receiving renal allografts with prolonged
cold ischemia times resulted in lower incidence of de-
layed graft function and improvement in long-term sur-
vival [28]. Nevertheless, multiple toxicities of OKT3 such
as the cytokine release syndrome, development of anti-
murine antibodies, and increased risk of thromboembolic
events hinder widespread use in patients with delayed
graft function [29].
CONCLUSION
Although FTY720 may be considered a “deple-
tional drug,” unlike other depletion strategies, FTY720
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advantageously does not deplete lymphocytes from
lymph nodes and thereby does not induce general im-
munosuppression [4]. Furthermore, unlike standard im-
munosuppressive drugs, FTY720 does not interfere with
lymphocyte activation, proliferation, or memory [30].
FTY720 neither affects cytokine production [31] nor the
B-cell antibody production at therapeutic concentrations
[3]. We eagerly await evaluation of the ongoing phase
II and III, employing FTY720 for rejection prophylaxis.
We envision that tailoring of initial immunsuppression
directed at the prevention of delayed graft function in
parallel with rejection prophylaxis will be considered in
design of future clinical studies.
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